Expert Insights

Conference Coverage

Addition of Ovarian Function Suppression to Antihormonal Therapy Demonstrates Promise in HR-Positive, HER2-Positive Early Breast Cancer

10/31/2024

Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...

Sung Gwe Ahn, MD, PhD, discusses...

10/31/2024

Oncology

Conference Coverage

Assessing HER2-Low/-Ultralow Status Could Change Treatment Landscape for Patients With HR-Positive Metastatic Breast Cancer

10/29/2024

Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...

Giuseppe Viale, MD, discusses...

10/29/2024

Oncology

Conference Coverage

Exploring the Current Treatment Landscape for Patients With Extramedullary MM

10/29/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Saad Usmani, MD, discusses optimal strategies and the current treatment landscape for patients with extramedullary multiple myeloma.

At the 2024 Lymphoma, Leukemia &...

10/29/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Novel Advancements in Marginal Zone Lymphoma Research

10/29/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.

At the 2024 Lymphoma, Leukemia &...

10/29/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Best Management of a Patient With BRAF-Altered Recurrent or Refractory Pediatric Low-Grade Glioma

10/28/2024

Matthew Cascio, MD, discusses the course of treatment he would take for a patient with BRAF V600E-mutated pediatric ganglioglioma.

Matthew Cascio, MD, discusses...

10/28/2024

Oncology

Conference Coverage

Identifying Unmet Clinical Needs in Treating Patients With Extramedullary MM

10/28/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.

At the 2024 Lymphoma, Leukemia &...

10/28/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Exploring the Immune Microenvironment in Multiple Myeloma Treatment

10/25/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...

At the 2024 Lymphoma, Leukemia &...

10/25/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Advances in Risk Stratification and Treatment for Patients With AML

10/24/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.

At the 2024 Lymphoma, Leukemia &...

10/24/2024

Oncology

Conference Coverage

Treatment Options for When Immune Therapies Fail Among Patients With R/R MM

10/24/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with  R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...

At the 2024 Lymphoma, Leukemia &...

10/24/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Highlights in Indolent Lymphomas From the LL&M Congress

10/23/2024

In part 1 of this expert roundtable covering updates in lymphoma from the 2024 Lymphoma, Leukemia & Myeloma Congress, John Leonard, MD, discusses research in indolent lymphomas, highlighting follicular lymphomas, with Matthew Lunning, DO,...

In part 1 of this expert...

10/23/2024

Lymphoma, Leukemia & Myeloma Network

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology